CHMP thumbs-up for Bayer's Nexavar
German drugmaker Bayer Healthcare AG and the USA's Onyx Pharmaceuticals say they have received a positive opinion from the Committee for Medicinal Products for Human Use regarding their co-developed anticancer agent Nexavar (sorafenib). The drug is being assessed as a treatment for patients with advanced renal cell carcinoma or kidney cancer, who have experienced failed interferon-alpha or interleukin-2 based therapy.
The product, which is designed as a film-coated 200mg dose, has demonstrated the ability to double the rate of progression-free survival in patients with advanced RCC (Marketletter February 27).
The company added that the compound, which received approval for use in the treatment of RCC from the US Food and Drug Administration in December of last year, has also been granted clearance by the Mexican Ministry of Health for use by RCC and kidney cancer patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze